Cspc Pharmaceutical

Cspc Pharmaceutical's reported carbon emissions

CSPC Pharmaceutical, headquartered in HK, reported total emissions of approximately 967,877,000 kg CO2e for 2024, comprising Scope 1 emissions of about 474,567,040 kg CO2e and Scope 2 emissions of approximately 493,310,000 kg CO2e. In 2023, the company's total Scope 1 and 2 emissions were approximately 1,081,261,000 kg CO2e. Prior to that, in 2022, total Scope 1 and 2 emissions stood at approximately 1,137,042,000 kg CO2e, and in 2021, they were about 1,181,000,000 kg CO2e. For 2020, CSPC Pharmaceutical's Scope 1 and 2 emissions totalled approximately 1,047,584,000 kg CO2e. In 2019, Scope 1 and 2 emissions were approximately 1,124,435,000 kg CO2e. The company has set intensity reduction targets: a 53% reduction in greenhouse gas emissions per unit revenue by 2024-2026, a 56% reduction by 2027-2028, and a 60% reduction by 2029-2030, all referencing a 2017 baseline for Scope 1 and 2 intensity. CSPC Pharmaceutical also aims to reduce Scope 2 emissions per unit revenue by 53% for 2024-2026 and by 56% for 2027-2028, again using 2017 as a baseline. The company indicated in 2021 its commitment to align with the Task Force on Climate-related Financial Disclosures (TCFD) recommendations. Scope 3 emissions data was not available for the reported years, with a noted missing data point for purchased goods and services.